Literature DB >> 21349558

[Usefulness of FRAX tool for the management of osteoporosis in the Spanish female population].

Rafael Azagra Ledesma1, Daniel Prieto-Alhambra, Gloria Encabo Duró, Enrique Casado Burgos, Amada Aguyé Batista, Adolfo Díez-Pérez.   

Abstract

BACKGROUND AND
OBJECTIVE: Osteoporotic fractures involve a significant consumption of health resources. Bone densitometry has been essential in the management of osteoporosis. However, for fracture absolute risk prediction, other important clinical risk factors are also important. WHO published a risk estimation tool (FRAX), and the National Osteoporosis Guideline Group (NOGG) reported thresholds for densitometry assessment based on cost-effectivity criteria. Our goal is to determine the diagnostic predictive validity of FRAX in our population, and to assess how its use (according to NOGG guidelines) would modify the current number of referrals to DXA scan in our health system. SUBJECTS AND METHODS: Diagnostic validation study in a consecutive sample of 1,650 women, 50 to 90 years old, under no treatment with anti-resortives, from the FRIDEX cohort. DXA and a questionnaire regarding risk factors were performed. ROC curve and area under the curve (AUC) were used to assess FRAX's diagnostic validity for femoral neck osteoporosis (FNOP). Risk of fracture was calculated using FRAX pre and postDXA, and women were classified according to their risk, following NOGG recommendations.
RESULTS: FRAX's ROC AUC for FNOP was 0.812 for major fracture and 0.832 for hip fracture. Using FRAX according to NOGG would result in performing only 25.2% of the current tests. If we added previous fracture antecedent to the algorithm, 49.4% of the tests performed would be advised.
CONCLUSIONS: The use of NOGG thresholds applied to FRAX would reduce about 50% the current number of referrals to DXA scan in our population. FRAX has a good diagnostic validity for FNOP.
Copyright © 2010 Elsevier España, S.L. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21349558     DOI: 10.1016/j.medcli.2010.09.043

Source DB:  PubMed          Journal:  Med Clin (Barc)        ISSN: 0025-7753            Impact factor:   1.725


  6 in total

1.  [New evidence on the discriminant and predictive capacity of the FRAX(®) tool in a Spanish female population].

Authors:  Rafael Azagra; Gloria Encabo; Amada Aguyé; Milagros Iglesias
Journal:  Aten Primaria       Date:  2011-10-21       Impact factor: 1.137

2.  [Precautions required on using the predictive thresholds of the FRAX® tool to decide the need for an axial bone density scan in the Spanish population].

Authors:  Rafael Azagra; Marta Zwart; Amada Aguyé; Gloria Encabo
Journal:  Aten Primaria       Date:  2011-08-19       Impact factor: 1.137

3.  Prevalence of osteoporotic fracture risk factors and antiosteoporotic treatments in the Valencia region, Spain. The baseline characteristics of the ESOSVAL cohort.

Authors:  J Sanfélix-Genovés; G Sanfélix-Gimeno; S Peiró; I Hurtado; C Fluixà; A Fuertes; J C Campos; V Giner; C Baixauli
Journal:  Osteoporos Int       Date:  2012-05-23       Impact factor: 4.507

4.  Measuring health-related quality of life in men with osteoporosis or osteoporotic fracture.

Authors:  Marta Zwart; Rafael Azagra; Gloria Encabo; Amada Aguye; Genís Roca; Sílvia Güell; Núria Puchol; Emili Gene; Francesc López-Expósito; Silvia Solà; Sergio Ortiz; Pilar Sancho; Liz Abado; Milagros Iglesias; Jesus Pujol-Salud; Adolf Diez-Perez
Journal:  BMC Public Health       Date:  2011-10-09       Impact factor: 3.295

5.  Changing trends in the epidemiology of hip fracture in Spain.

Authors:  R Azagra; F López-Expósito; J C Martin-Sánchez; A Aguyé; N Moreno; C Cooper; A Díez-Pérez; E M Dennison
Journal:  Osteoporos Int       Date:  2013-12-10       Impact factor: 4.507

6.  FRAX® tool, the WHO algorithm to predict osteoporotic fractures: the first analysis of its discriminative and predictive ability in the Spanish FRIDEX cohort.

Authors:  Rafael Azagra; Genís Roca; Gloria Encabo; Amada Aguyé; Marta Zwart; Sílvia Güell; Núria Puchol; Emili Gene; Enrique Casado; Pilar Sancho; Silvia Solà; Pere Torán; Milagros Iglesias; Maria Carmen Gisbert; Francesc López-Expósito; Jesús Pujol-Salud; Yolanda Fernandez-Hermida; Ana Puente; Mireia Rosàs; Vicente Bou; Juan José Antón; Gustavo Lansdberg; Juan Carlos Martín-Sánchez; Adolf Díez-Pérez; Daniel Prieto-Alhambra
Journal:  BMC Musculoskelet Disord       Date:  2012-10-22       Impact factor: 2.362

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.